calendar
6,562 catalysts · 3,603 8k filing · 1,000 device adverse event · 775 grant · 578 earnings · 234 approval · 172 phase 2 completion
next 91 dayslessmore
MonWedFri
6,562 catalysts · 3,603 8k filing · 1,000 device adverse event · 775 grant · 578 earnings · 234 approval · 172 phase 2 completion
Items: 5.07, 9.01
Items: 8.01, 9.01
Items: 2.05
Items: 7.01, 8.01, 9.01
Items: 2.02
Items: 1.01, 7.01, 9.01
Items: 5.02, 7.01, 9.01
Items: 1.01, 9.01
Items: 7.01, 9.01
Items: 2.02, 9.01
Items: 2.02, 7.01, 9.01
Items: 1.01, 7.01, 9.01
Items: 8.01, 9.01
Items: 8.01, 9.01
Items: 8.01, 9.01
Items: 7.01, 9.01
Items: 7.01, 8.01, 9.01
Items: 5.02, 9.01
Items: 1.01, 3.02, 8.01, 9.01
Items: 7.01, 8.01, 9.01
Items: 3.02, 9.01
Items: 2.02, 9.01
Items: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
Items: 2.02, 7.01
Items: 5.02
Items: 2.02, 9.01
Items: 8.01, 9.01
Items: 5.02, 9.01
Items: 8.01
Items: 5.02
Items: 7.01, 9.01
Items: 7.01, 9.01
Items: 5.02
Items: 5.02
Items: 8.01
Items: 2.02, 9.01
Items: 1.01
Items: 5.02
Items: 3.01
Items: 1.01, 3.02, 5.01, 5.02, 5.03, 5.07, 9.01
Items: 3.01, 7.01, 9.01
Items: 8.01, 9.01
Therapy area: Metabolic Disorders. Indication: Type 1 Diabetes (Juvenile Diabetes)
Therapy area: Oncology. Indication: Hepatocellular Carcinoma, Liver Cancer
Therapy area: Oncology. Indication: Cervical Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Gastric Cancer, Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hepatocellular Carcinoma, Hypopharyngeal Cancer, Laryngeal Cancer, Malignant Pleural Mesothelioma, Melanoma, Non-Small Cell Lung Carcinoma, Oral Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Cancer, Re
Therapy area: Cardiovascular. Indication: Cerebrovascular Disease, Ischemia
Therapy area: Hematological Disorders. Indication: Hemophilia A (Factor VIII Deficiency)
Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer
Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19)
Therapy area: Metabolic Disorders. Indication: Phenylketonuria (PKU)